Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .The major indexes continue to grind up despite increasing signs of trouble in the jobs and housing markets. Despite this, headline economic growth appears strong. Q2 GDP just got revised up again this weekBret leads the investing group ...

NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

近期IPO活动 - 过去一周左右一些首次公开募股引发内部人士大举买入[1]

Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shares of the Company’s common stock, $0.00001 par value per share, for an aggregate purchase price of approximately $12.9 million. Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investors. The Ser ...

Exelixis, Inc. (NASDAQ:EXEL) ranks among the most undervalued NASDAQ stocks to buy now. On September 17, Barclays began coverage of Exelixis, Inc. (NASDAQ:EXEL), rating it Equalweight and setting a price target of $40 on the company’s shares. The firm forecasts cabozantinib, Exelixis’ major value driver, will climb in the mid-single digits until its patent expires in 2029. Photo by National Cancer Institute on Unsplash Barclays predicts overall revenue for 2029 to be around 8% lower than consensus, owin ...

安进公司美国制造扩张 - 安进宣布投资6.5亿美元扩建波多黎各Juncos生物制剂工厂[2] - 该投资直接回应特朗普对品牌和专利药品征收100%关税的威胁[2] - 预计创造750个就业岗位包括建筑和技能制造岗位[2] - 公司自2017年底已在美国制造和研发投入超400亿美元[3] - 今年早些公司宣布俄亥俄州9亿美元扩建和北卡罗来纳州10亿美元新建设施[3] 星巴克北美业务重组 - 星巴克计划9月底前关闭434家北美门店[4] - 门店数量将从6月18734家减少至18300家[4] - 裁员900名非零售员工作为转型计划部分[4] - 关闭原因为财务不稳定或无法提供预期客户体验[5] - 公司计划下财年增加北美门店数量并重新设计超1000家门店[5] 中国工业利润复苏 - 8月工业利润同比增长20.4%较7月下降1.5%大幅改善[6] - 1-8月累计工业利润增长0.9%至4.69万亿元人民币[6] - 反弹表明制造业潜在稳定化[7] - 利润显著增长可能提升投资者信心支持经济复苏[7] 摩根大通增持阿里巴巴 - 摩根大通对阿里巴巴持股从6.81%增至12.29%[10] - 增持发生在9月22日通过香港交易所披露[10] - 表明机构投资者对科技板块看涨情绪增强[11] - 科技增长板块受益于全球AI发展和国内算力需求提升[11]

Key Points The biotech launched a late-stage trial of a non-vaccine flu preventative. There is a vast addressable market for such a product. 10 stocks we like better than Cidara Therapeutics › Cidara Therapeutics (NASDAQ: CDTX) had some encouraging news to deliver at the end of the trading week, and investors traded the biotech's stock up as a result. It closed Friday nearly 7% higher in price, easily outpacing the 0.6% increase of the bellwether S&P 500 index. Phase 3 trial begins for investigatio ...

BREAKING: Bullish Rebound Pares Market's Weekly Losses Shares of Crinetics Pharmaceuticals (CRNX) surged Friday after the Food and Drug Administration approved the company's acromegaly drug, Palsonify. Acromegaly is a rare condition in which the pituitary gland produces too much growth hormone. This causes some bones, organs and other tissues to grow bigger. The late wrestler and actor Andre Rene Roussimoff — widely known as "Andre the Giant" — suffered from acromegaly. Palsonify will cost $290,000 a year, ...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in our press rel ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast. ...